|Number of samples:||50|
|Release date:||Nov 13 2018|
|Last update date:||Nov 29 2018|
|Diseases:||Adenocarcinoma, Brain Neoplasms, Ductus Arteriosus, Patent, Neoplasms|
|Dataset link||TP63-mediated enhancer reprogramming drives the squamous subtype of pancreatic ductal adenocarcinoma (ChIP-seq)|
H3K27ac ChIP-seq was performed using antibody recognizing endogenous protein with input genomic DNA as control with/without transduction of sgNEG/sgTP63#2/sgTP63#4 (BxPC3 cells) or MTV/TP63ΔN (SUIT2 cells). TP63 ChIP-seq in BxPC3 cells was performed using antibody recognizing endogenous protein with input genomic DNA as control. FLAG-TP63 ChIP-seq in SUIT2 cells was performed in FLAG-TP63 expressing cells with input genomic DNA as control.